UAE Myasthenia Gravis Drugs Market Report 2023 to 2030

UAE Myasthenia Gravis Drugs Market Analysis

$ 3999

UAE Myasthenia Gravis Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for myasthenia gravis is rising due to increasing prevalence and incidence of disease, improved diagnostic techniques, increased awareness and better understanding of the disease, Supportive Government Initiatives like providing financial support, improving healthcare infrastructure, promoting research in rare diseases and Technological Advancements in drugs and therapies treating myasthenia gravis. Major global players in Myasthenia Gravis Drugs Market are Alexion Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Amneal Pharmaceuticals LLC, Zydus Cadila, Avadel, Dr. Reddy's Laboratories, Ltd., Fresenius Kabi, AG, Endo Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc., Mylan N.V., Aurobindo Pharma, Pfizer, Inc., Astellas Pharma, Inc.

ID: IN10AERD102 CATEGORY: Rare Diseases GEOGRAPHY: UAE AUTHOR: Sakshi Mantri

Buy Now

UAE Myasthenia Gravis Drugs Market Analysis Summary

UAE Myasthenia Gravis Drugs Market is valued at around $6.6 Mn in 2022 and is projected to reach $12.68 Mn by 2030, exhibiting a CAGR of 8.5% during the forecast period 2023-2030.

Myasthenia gravis (MG) is an autoimmune neuromuscular disorder that affects the communication between nerves and muscles. Muscles of the eyes, face, and swallowing are the most commonly affected muscles in the body. The weakening of these muscles can result in double vision, drooping eyelids, trouble talking, and trouble walking. Medication can help with the signs and symptoms of myasthenia gravis, which include muscle weakness in the arms or legs, double vision, drooping eyelids, and difficulties breathing, speaking, chewing, and swallowing. The illness, however, has no known treatment. Cholinesterase Inhibitors act by increasing the levels of enzyme acetylcholine by inhibiting the enzyme acetylcholine esterase like pyridostigmine. Immunosuppressants act by suppressing the immune system to reduce the production of antibodies that attack the neuromuscular junction. Commonly used immunosuppressants include prednisone, azathioprine and methotrexate. Monoclonal Antibodies and Biologics like rituximab and eculizumab. Major global players in Myasthenia Gravis Drugs Market are Alexion Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Amneal Pharmaceuticals LLC, Zydus Cadila, Avadel, Dr. Reddy's Laboratories, Ltd., Fresenius Kabi, AG, Endo Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc., Mylan N.V., Aurobindo Pharma, Pfizer, Inc., Astellas Pharma, Inc.

Market Dynamics

Market Drivers

As more people develop neuromuscular conditions affecting the muscles, neuromuscular junctions, peripheral nerves, nerve plexuses, spinal nerve roots, and/or cranial and spinal motor neurons, the market for treatments will grow faster. Additionally, it is projected that increased patient understanding of the condition will promote market growth.
Additional growth factors that help the market rise include the continuing clinical trials that pharmaceutical companies are performing to develop innovative medicines. The strong pipeline of possible drugs and the range of options will drive even more growth in the market for myasthenia gravis therapy.
The market for myasthenia gravis will also expand due to advancements in medical technology, expanding government initiatives to increase awareness, and increased public support.
Improved diagnostic techniques like antibody testing, electromyography (EMG) and imaging techniques. All these act as market growth drivers.

Market Restraints

The market for myasthenia gravis disease will continue to grow, but it may take longer due to the high price of associated drugs and therapies as well as competition from off-label drugs, Limited Efficacy and Variability of available drugs, Adverse Effects and Safety Concerns like liver problems and gastrointestinal problems, disease complexity and heterogeneity and lack of predictive biomarkers. All these act as market growth restraints.

Market Developments

In June 2020, Argenx began spreading the word about myasthenia gravis. The campaign's launchpads included a virtual conference, light-up events held around the country, the launch of a patient website, and the announcement of a forthcoming documentary.

Key players

Sanofi Pfizer Ionis Pharmaceuticals Catalyst Pharmaceuticals Acorda Therapeutics Alexion Pharmaceuticals Novartis Roche Teva Pharmaceutical Industries Acceleron Pharma

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For UAE Myasthenia Gravis Drugs Market

By Diagnosis:

Edrophonium Test
Blood Test
Repetitive Nerve Stimulation
Single-fiber electromyography (EMG)
Others

By Treatment:

Cholinesterase Inhibitors
Corticosteroids
Immunosuppressants
Plasmapheresis
Autologous Hematopoietic Stem Cell
Transplantation (HSCT)
Surgery

By End-user

Hospital and Clinics
Diagnostic Laboratories
Homecare
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.